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Abstract
Objective: To evaluate the correlation between interleukin 10 (IL-10) 1082A/G polymorphism
(rs1800896) and breast cancers by performing a meta-analysis.
Methods: The Embase and Medline databases were searched through 1 September 2018 to
identify qualified articles. Odds ratios (OR) and corresponding 95% confidence intervals (CIs)
were applied to evaluate associations.
Results: In total, 14 case-control studies, including 5320 cases and 5727 controls, were analyzed.
We detected significant associations between the IL10 1082 G/G genotype and risk of breast
cancer (AA þ AG vs. GG: OR ¼ 0.88, 95% CI ¼ 0.80–0.97). Subgroup analyses confirmed a significant association in Caucasian populations (OR ¼ 0.89, 95% CI ¼ 0.80–0.99), in populationbased case-control studies (OR ¼ 0.87, 95% CI ¼ 0.78–0.96), and in studies with 500 subjects
(OR ¼ 0.88, 95% CI ¼ 0.79–0.99) under the recessive model (AA þ AG vs. GG). No associations
were found in Asian populations.
Conclusions: The IL10 1082A/G polymorphism is associated with an increased risk of breast
cancer. The association between IL10 1082 G/G genotype and increased risk of breast cancer is
more significant in Caucasians, in population-based studies, and in larger studies.
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Introduction
Breast cancer is regarded as the most
common cancer among women, and about
6.6% of cases are diagnosed among women
40 years old or younger.1 Breast cancer
accounts for 40% of all types of cancers
diagnosed in women and is the thirdleading cause among all cancer deaths in
Western countries,2 although the death
rate has decreased in most developed countries with the help of improved treatments
and earlier diagnosis.
Over the last few years, several mechanisms have been postulated regarding the
etiology and progression of breast cancer.3
It has been shown that chronic inflammatory responses play essential roles in development of all kinds of cancers. Inflammatory
cells can regulate the tumor microenvironment and are clearly implicated in tumor
development by facilitating proliferation,
migration, and survival.4,5 Several cytokines, including interferon-a, interleukin
(IL)-2, IL-6, IL-8, IL-10, and tumor necrosis factor-a, have essential and coordinated
functions in breast carcinogenesis.6,7 As a
multifunctional anti-inflammatory cytokine, IL-10 represses the inflammatory
response to tumor microenvironments. It
is usually secreted by immune cells, such
as monocytes, T cells, macrophages (if stimulated appropriately), certain subsets of
dendritic cells, and B cells.8,9
The human IL10 gene, containing five
exons, is located on chromosome 1q32.1.
The promoter region contains at least 40
polymorphic sites, and these sites may
affect gene transcription.10–12 An A-to-G
single base pair substitution designated
rs1800896 (1082A/G) has been found in
the IL10 gene promoter region, located
1082 bp (upstream) of the transcriptional
start site. The IL10 1082A/G polymorphism is closely connected to IL-10 expression.13–15 However, there is currently no
agreement on whether an association
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exists between breast cancer and the
1082A/G polymorphism. This metaanalysis was designed to clarify whether
rs1800896 (1082A/G) is associated with
breast cancer risk through an investigative
analysis of the published literature.

Methods
Identification and selection of studies
Relevant studies from Medline (since
1 January 1966) and Embase (since
1 January 1974) through 1 September
2018 were systematically searched (by
Z. Zhu and J.-B. Liu). Eligible studies
were identified using the keywords
“IL-10”, “Interleukin-10”, “-1082 A/G”,
“rs1800896”, “polymorphism”, “genotype”,
“mutation” “variant”, and “breast cancer”.
Then, all references of retrieved studies, clinical trials, review articles, and previous metaanalyses were examined to identify relevant
studies that may have been missed in the
electronic database searches. The complete
search strategy is shown in the supplementary data (Supplemental Document 1).

Eligibility criteria
Eligible studies had to meet the following
criteria: (1) evaluated the connection
between IL10 1082A/G polymorphism
and breast cancer risk; (2) characterized by
a case-control or cohort design; (3) provided
enough data for calculation of odds ratios
(ORs) and their 95% confidence intervals
(95% CIs). If multiple studies presented the
same data, only the study with the latest
data, the largest sample size, or the completed study was included. The exclusion criteria
were (1) review article, case report, or an
abstract only; (2) studies without a casecontrol population or not a cohort design;
(3) lack of essential data; (4) studies without
a control group of healthy individuals; and
(5) duplicates of previous prior articles.
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Data collection and quality evaluation
From the eligible studies, two authors
(Z. Zhu and J.-B. Liu) independently collected relevant data, if available: first
author, publication year, country of
origin, ethnicity of patients, total numbers
of cases and controls, genotype frequencies,
genotyping technique, minor allele frequency, and P-value for Hardy–Weinberg
equilibrium (HWE). For any disagreements between the two data sets, consensus was reached through discussion or
following assessment by a third author. In
control groups, confirmation of HWE was
applied to assess the quality of study: highquality studies have HWE confirmation in
controls whereas low-quality ones do not.

Quality assessment of included studies
The Newcastle–Ottawa Scale (NOS) of
case-control studies was used to determine
the methodological quality for each included study. The NOS contains eight elements,
as shown in Supplemental Table 1.

Statistics
The correlation between the IL10 1082A/
G polymorphism (rs1800896) and breast
cancer risk was assessed by crude ORs
with 95% CIs. A summary estimate of the
OR was obtained by calculating the weighted average of the ORs for each study. The
Z-test was carried out to assess whether the
pooled OR was statistically significant. This
meta-analysis was based on the allele model
(A vs. G), the dominant model (AA vs.
AG þ GG), recessive model (AA þ AG vs.
GG), co-dominant heterozygote model
(AA vs. AG), co-dominant homozygote
model (AA vs. GG), and the overdominant model (AA þ GG vs. AG). In
the meta-analysis, heterogeneity between
studies was assessed using the I2 value and
the Q-statistic. The I2 value describes the
degree of heterogeneity between studies.
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A value of 0 to 25% indicates no detected
heterogeneity, 25% to 50% indicates lowly
increased heterogeneity, 50% to 75% moderately increased heterogeneity, and 75% to
100% highly increased heterogeneity.16,17
For the Q-statistic, a P-value >0.10 indicates
a lack of heterogeneity between studies. An
estimate of pooled OR was determined by
the fixed-effects model (Mantel–Haenszel
method).18 In addition, the random-effects
model (DerSimonian and Laird method)
was used.19 Subgroup analyses, HWE
status, and meta-regression were performed
to adjust the heterogeneity between studies.
In controls, a departure from HWE was
evaluated using the v2 test. A P-value
<0.05 represents statistical significance.
Analyses of one-way sensitivity were made
to evaluate the stability of results. That is,
with each calculation, one study was
removed from the meta-analysis so that the
effect of an individual dataset on the pooled
OR could be determined. Any potential publication bias was identified by using funnel
plots and Egger’s linear regression test.20,21
To guarantee the accuracy and reliability of
the results, data were entered independently
by two researchers and consensus was
reached. Comprehensive Meta-Analysis
software version 2.20 (Stata Corp., College
Station, TX, USA) was applied to perform
all data analyses. All P-values were twosided and considered significant if P < 0.05.

Patient and public involvement
There was no direct patient or public
involvement in current study and therefore
ethical approval and patient consent were
not required.

Results
Study characteristics
As shown in Figure 1, our search criteria
returned 253 published articles. Fourteen
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Figure 1. PRISMA flow chart depicting the procedure for the identification of studies.

studies,22–35 containing 5320 breast cancerrelated cases and 5727 control cases, were
identified. A meta-analysis database was
established based on the information
extracted from the 14 selected studies:
8 (57%) focused on Caucasian populations,
4 (29%) on Asian populations, 1 (7%) on
African populations, and 1 (7%) had a
mixed population.
All 14 studies included cases and controls.
Nine (64%) studies were population-based
and 5 (36%) were hospital-based. They used

a range of gene detection methods: PCR,
restriction fragment length polymorphism
(RFLP)-PCR,
amplification-refractory
mutation system (ARMS)-PCR, allelespecific (AS)-PCR), and sequence-specific
amplification (SSP)-PCR. Sample size
varied greatly across studies, from a minimum of 62 to a maximum of 4483. For
controls, all genotype distributions were
consistent with HWE for the IL10 1082
A/G polymorphism. Details are shown in
Table 1.

Italy
UK
USA
UK
Italy
Canada
UK
Turkey
China
USA
India
India
Egypt
Jordan

Sample
type

Blood
Blood
Blood
Blood
Blood
Blood
Blood
Blood
Blood
Blood
Blood
Blood
Blood
Blood

Giordani (2003)
Smith (2004)
Guzowski (2005)
Balasubramanian (2006)
Scola (2006)
Onay (2006)
Pharoah (2007)
Gonullu (2007)
Kong (2010)
Schonfeld (2010)
Pooja (2012)
Vinod (2015)
AlSuhaibani (2015)
Atoum (2016)

Study

Giordani (2003)
Smith (2004)
Guzowski (2005)
Balasubramanian (2006)
Scola (2006)
Onay (2006)
Pharoah (2007)
Gonullu (2007)
Kong (2010)
Schonfeld (2010)
Pooja (2012)
Vinod (2015)
AlSuhaibani (2015)
Atoum (2016)

HB
PB
HB
PB
HB
PB
PB
HB
HB
PB
PB
PB
PB
PB

Control
source

11
39
12
121
16
103
344
3
1
200
68
18
17
16

GG
54
58
28
253
40
205
1003
22
29
417
0
31
47
29

AG

Genotype frequency (case)

Caucasian
Caucasian
Mixed
Caucasian
Caucasian
Caucasian
Caucasian
Caucasian
Asian
Caucasian
Asian
Asian
African
Asian

Ethnicity

60
32
10
123
28
90
695
13
285
219
132
76
16
157

AA

ARMS-PCR
ARMS-PCR
PCR
PCR
SSP-PCR
PCR
PCR
PCR
RELP-PCR
PCR
RELP-PCR
AS-PCR
PCR
PCR

Genotyping
method
100
263
25
498
110
372
2280
24
322
1083
200
160
80
210

No. of
controls

16
57
4
117
21
71
346
1
2
230
55
15
16
17

GG
51
120
12
260
45
194
1096
7
35
530
0
78
50
42

AG

Genotype frequency
(control)

125
144
50
497
84
398
2203
38
315
859
200
125
80
202

No. of
cases

33
46
9
121
40
107
743
16
285
322
145
67
14
151

AA

0.61
0.24
1
0.32
0.21
0.31
0.08
0.83
0.42
0.66
NA
0.25
NA
NA

HWE

174
122
48
499
96
385
2393
48
599
834
264
183
81
343

A

Allele
frequency
(case)

82
136
52
497
72
411
1691
28
31
817
136
67
79
61

G

117
212
30
502
125
408
2582
39
605
1176
290
212
82
344

A

Allele
frequency
(control)

83
234
20
494
87
336
2480
9
39
990
110
108
78
76

G

5
4
6
3
5
4
4
5
6
3
4
3
4
3

Quality
score

HB, hospital-based; PB, population-based; RELP-PCR, restriction fragment length polymorphism-PCR; ARMS, amplification-refractory mutation system-PCR; AS-PCR, allelespecific-PCR; SSP-PCR, sequence-specific amplification-PCR; HWE, Hardy–Weinberg equilibrium.

Country

Study

Table 1. Characteristics of studies (listed by first author and year) included in the meta-analysis.

Zhu et al.
5

0.32
0.54
1.21 (0.83, 1.74)
1.03 (0.94, 1.12)
HCC, hospital-based case-control study; PCC, population-based case-control study.
*AA þ AG vs. GG and AA vs. GG, the fixed effect model due to the heterogeneity; otherwise, the random effect model.

0.6
0.03
0.46
0.59
(0.80, 1.25) 0.99 1.06 (0.74, 1.51) 0.76 0.86 (0.69, 1.07) 0.18 1.18 (0.76, 1.81)
(0.84, 1.02) 0.13 0.93 (0.81, 1.07) 0.3 0.88 (0.79, 0.99) 0.03 0.97 (0.88, 1.08)

0.94 (0.73, 1.20)
0.86 (0.76, 0.98)

0.66
0.06
0.91 (0.60, 1.38)
1.18 (1.00, 1.40)
0.61
0.02
0.55
0.23
(0.62, 1.44) 0.79 0.85 (0.47, 1.53) 0.58 1.18 (0.74, 1.88) 0.48 0.84 (0.48, 1.48)
(0.86, 1.04) 0.27 1.02 (0.86, 1.22) 0.81 0.87 (0.78, 0.96) 0.01 1.14 (0.92, 1.42)

1.14 (0.69, 1.89)
0.87 (0.77, 0.97)

0.59
0.04
1.03 (0.92, 1.16)
1.73 (1.03, 2.91)
0.05
0.35
0.76
0.03
(0.84, 1.06) 0.33 0.95 (0.78, 1.14) 0.56 0.89 (0.80, 0.99) 0.04 0.97 (0.81, 1.16)
(0.80, 1.52) 0.55 1.27 (0.81, 1.98) 0.3 0.78 (0.56, 1.07) 0.12 1.73 (1.04, 2.86)

0.88 (0.78, 1.00)
0.86 (0.62, 1.19)

0.12
1.13 (0.97, 1.32)
0.03
0.88 (0.78, 0.98)
0.38
(0.87, 1.08) 0.55 1.02 (0.85, 1.21) 0.85 0.88 (0.80, 0.97) 0.01 1.09 (0.90, 1.33)

Overall
0.97
Ethnicity
Caucasian 0.94
Asian
1.10
Control source
HCC
0.94
PCC
0.95
Sample size
<500
1.00
500
0.93

OR (95% CI)
P
OR (95% CI)
P
OR (95% CI)

P

OR (95% CI)

P

OR (95% CI)

P

OR (95% CI)

AA vs. GG* (co-dominant
homozygotes model)
AA vs. AG (co-dominant
heterozygotes model)
AA þ AG vs. GG*
(recessive model)
AA vs. AG þ GG
(dominant model)

After stratifying the data for ethnicity, we
observed that in Caucasian populations,
based on eight studies (4348 patients and
4730 control cases), an obvious association
was found between IL10 1082 G/G genotype and increased risk of breast cancer in
the recessive model (AA þ AG vs. GG:
OR ¼ 0.89, 95% CI ¼ 0.80–0.99; P ¼ 0.04;
Table 2 and Figure 3a) and the codominant homozygotes model (AA vs.
GG: OR ¼ 0.88, 95% CI ¼ 0.78–1.00;
P ¼ 0.05; Table 2 and Figure 3b).
However, in Asian groups, there was no
association between IL10 1082 G/G polymorphism and increased breast cancer risk
in any model (Table 2, Figure 3a and 3b).

A vs. G

Subgroup analysis by ethnicity

Table 2. The meta-analysis of IL10 1082A/G polymorphism and breast cancer risk.

Fourteen separate studies, including 5320
breast cancer cases and 5727 control
cases, were identified to explore associations. The key findings are demonstrated
in Table 2. There was an overall significant
association as determined by both the
recessive model (AA þ AG vs. GG:
OR ¼ 0.88, 95% CI ¼ 0.80–0.97; P ¼ 0.01;
Figure 2a) and the co-dominant homozygotes model (AA vs. GG: OR ¼ 0.88, 95%
CI ¼ 0.78–0.98; P ¼ 0.03; Figure 2b). The
results showed an association of IL10
1082 G/G genotype with increased
breast cancer risk. However, no obvious
association was found between the frequency of the IL10 1082 A/G polymorphism
and breast cancer as determined by the
allele model (A vs. G: OR ¼ 0.97, 95%
CI ¼ 0.87–1.08), the dominant model (AA
vs. AG þ GG: OR ¼ 1.02, 95% CI ¼ 0.85–
1.21), the co-dominant heterozygotes model
(AA vs. GA: OR ¼ 1.09, 95% CI ¼ 0.9–
1.33), or the over-dominant model
(AA þ GG vs. AG: OR ¼ 1.13, 95%
CI ¼ 0.97–1.32).

AA þ GG vs. AG
(over-dominant model)

Overall data

P
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Figure 2. Forest plot of breast cancer risk in all studies (overall) associated with the IL10 1082A/G
(rs1800896) polymorphism under (a) the recessive model (AA þ AG vs. GG), and (b) the co-dominant
homozygotes model (AA vs. GG). IL10, interleukin-10 gene, OR, odds ratio; 95% CI, 95% confidence
interval.

Figure 3. Forest plot of breast cancer risk in ethnicity subgroups (Caucasian vs. Asian) associated with the
IL10 1082A/G (rs1800896) polymorphism under (a) the recessive model (AA þ AG vs. GG), and (b) the
co-dominant homozygotes model (AA vs. GG). IL10, interleukin-10 gene, OR, odds ratio; 95% CI, 95%
confidence interval.

Subgroup analysis by study design
In the study design subgroups, pooled analyses of population-based case-control studies showed a close association of IL10

1082 G/G genotype with an increase in
breast cancer risk based on the recessive
model (AA þ AG vs. GG: OR ¼ 0.87, 95%
CI ¼ 0.78–0.96; P ¼ 0.01; Table 2 and
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Figure 4a) and the co-dominant homozygotes model (AA vs. GG: OR ¼ 0.87, 95%
CI ¼ 0.77–0.97; P ¼ 0.02; Table 2 and
Figure 4b). None of the ORs in
hospital-based case-control studies were
statistically significant (Table 2 and
Figure 4a and 4b).

Subgroup analysis by sample size
We then stratified analyses by sample size,
with a cutoff of 500 subjects (i.e., sample
size <500 vs. 500).36 A higher risk
of breast cancer was observed in studies
with 500 subjects under the recessive
model (AA þ AG vs. GG: OR ¼ 0.88,
95% CI ¼ 0.79–0.99; P ¼ 0.03; Table 2
and Figure 5a) and the co-dominant
homozygotes model (AA vs. GG:
OR ¼ 0.86, 95% CI ¼ 0.76–0.98; P ¼ 0.03;
Table 2 and Figure 5b). In the subgroup
with sample size <500, there were no significant changes in ORs in any of the genetic
models.

Journal of International Medical Research

Publication bias
To evaluate the potential publication bias of
these studies, Egger’s test and Begg’s funnel
plots were used. For the recessive (AA þ AG
vs. GG) and co-dominant homozygote (AA
vs. GG) models, the findings from Begg’s
funnel plots showed no obvious asymmetry
(Figure 6a and 6b). The results of Egger’s
tests suggested no evidence of publication
bias for the recessive (AA þ AG vs. GG)
and co-dominant homozygote (AA vs.
GG) models (t ¼ 0.50, P ¼ 0.627; t ¼ 0.85,
P ¼ 0.411, respectively).

Discussion
Main findings
The findings from our meta-analysis of 14
studies, which involved 5320 cases and 5727
controls, indicated a significant correlation
between the IL10 1082 G/G genotype and
an increase in breast cancer risk. The significant association was confirmed in further

Figure 4. Forest plot of breast cancer risk in control source subgroups (hospital-based controls vs.
population-based controls) associated with the IL10 1082A/G (rs1800896) polymorphism under (a) the
recessive model (AA þ AG vs. GG), and (b) the co-dominant homozygotes model (AA vs. GG). IL10,
interleukin-10 gene, OR, odds ratio; 95% CI, 95% confidence interval.

Zhu et al.

9

Figure 5. Forest plot of breast cancer risk in sample size subgroups (<500 vs. 500 samples) associated
with the IL10 1082A/G (rs1800896) polymorphism under (a) the recessive model (AA þ AG vs. GG), and
(b) the co-dominant homozygotes model (AA vs. GG).
IL10, interleukin-10 gene, OR, odds ratio; 95% CI, 95% confidence interval.

Figure 6. Begg’s funnel plot of the publication bias test under (a) the recessive model (AA þ AG vs. GG),
and (b) the co-dominant homozygotes model (AA vs. GG). Each point represents a separate study for the
indicated association.
OR, odds ratio.

analyses among the Caucasian subgroup, the
population-based case-control subgroup,
and the subgroup of sample size 500.
Tumors are closely associated with
chronic inflammation.37 The multifunctional cytokine IL-10 is secreted by

T helper (Th)2 cells and has both immunosuppressive and anti-angiogenic functions,
suggesting that IL-10 is involved in tumor
development and progression. Some in vitro
studies have shown that IL-10 promotes the
proliferation and migration of MCF-7

10
breast cancer cells.38 Low expression of
IL10 in tumor cells increases the risk of
poor prognosis in breast cancer.39 Studies
have also shown that IL10 1082A/G polymorphisms (in the promotor region of
IL10) affect IL-10 expression,40 and that
the 1082 G allele is associated with
poorly differentiated adenocarcinoma of
breast cancer.41
Prior studies have explored the relationship between the IL10 1082A/G polymorphism and breast cancer risk but most failed
to find a correlation. Some studies report
that the AA genotype of the polymorphism
is correlated with an increase in breast
cancer risk,22,33 which is inconsistent with
the present study’s findings. However, the
limitations of those studies should be mentioned. Both included small sample sizes and
only reported GG, GA, and AA instead of
combined genotypes GG þ GA and
GA þ AA. Our paper represents the most
comprehensive meta-analysis on this issue,
and it expands on prior meta-analyses by
including a larger sample size as well as subgroup analyses. In particular, we believe that
the present research is the most accurate
meta-analysis to date because of the inclusion of a subgroup for study quality as determined by HWE status.
The incidence of gene polymorphisms
can vary substantially across racial or
ethnic populations with different genetic
backgrounds, which influences measures of
association between polymorphisms and
cancer susceptibility. Subgroup analyses
by ethnicity showed an obvious association
between GG genotypes and an increased
risk of breast cancer in Caucasian but not
Asian populations. These finding suggests
that genetic diversity or natural selection
is occurring at different rates in different
ethnicities. The sample size of the African
population was too small to draw conclusions on associations.
Subgroup analyses indicate that differences in either study design or the number of
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subjects affect the calculated risk associations. Significant associations between GG
genotypes and an increased risk of breast
cancer were identified in the populationbased case-control subgroup and the large
sample size (500) subgroup, but not in the
hospital-based case-control subgroup or the
small sample size (<500) subgroup.
Therefore, more rigorous and uniform studies should be conducted to accurately define
these associations.

Strengths and limitations
This study has several advantages. First, it is
a comprehensive and large meta-analysis that
evaluates the association of IL10 1082A/G
polymorphism with breast cancer risk, which
makes this study more powerful than prior
analyses. Second, meta-analysis results
showed that the GG genotype of the IL10
1082A/G polymorphism was associated
with an increased risk of breast cancer.
Finally, subgroup stratifications were
designed to exclude the influence of different
factors, making the statistical outcomes more
precise and reliable.
There are also several study limitations.
First, the raw data from the literature were
limited and some relevant studies were
excluded from the final analyses because
of inclusion criteria, as shown in Figure 1.
In three relevant articles, we could not
extract the data we wanted.42–44 Second,
the sample sizes in some subgroups were
small. Third, there were inconsistencies in
the types of controls across studies.
Control group samples included those
from population-based healthy individuals
and from hospitalized patients without
cancer. Thus, samples from control groups
may not represent the potential source population, especially in cases where the polymorphism affects the risk of other diseases.
Finally, this study was based on unadjusted
data. A more accurate study could be

Zhu et al.
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performed if data from individuals were
available.
Despite the above limitations, our metaanalysis suggested that the IL10 1082A/G
polymorphism (rs1800896) is closely
associated with breast cancer risk. Future
investigations to estimate the effects of
gene–gene and gene–environment interactions on breast cancer are necessary for a
better understanding of these interactions.
Stratification by ethnicity, cancer type,
study design, and sample size should be
standardized in future studies on the genetics of breast cancer, which should also
consider correlations between the IL10
1082A/G polymorphism and breast
cancer risk.
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Search Strategies
Medline by OVID
1. “interleukin-10” [MeSH Terms]
2. “interleukin-10” [All Fields]
3. “IL 10 ”[All Fields]
4. 1 OR 2 OR 3
5. “breast” [All Fields]
6. “neoplasms” [MeSH Terms]
7. “neoplasms” [All Fields]
8. “cancer” [All Fields]
9. 6 OR 7 OR 8
10. 5 AND 9
11. Polymorphism
12. 4 AND 10 AND 11
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Embase by OVID
1. “interleukin-10” [MeSH Terms]
2. “interleukin-10” [All Fields]
3. “IL 10” [All Fields]
4. 1 OR 2 OR 3
5. “breast” [All Fields]

Journal of International Medical Research
6. “neoplasms” [MeSH Terms]
7. “cancer” [All Fields]
8. 6 OR 7
9. 5 AND 8
10. Polymorphism
11. 4 AND 8 AND 10

